TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
CHRS

Coherus BioSciences Inc

Healthcare · Biotechnology

1.20$ +0.8% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Coherus BioSciences Inc (CHRS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 87.8% of the shares are freely tradable; institutional investors hold 38.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 38.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 18.7%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 87.8%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 16.0%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 155Mio.

Largest Shareholders

Institutions

Institutions CHRS
Name Stake (%) Shares Change (%) Date
BlackRock Inc 6.71 10,365,074 -1.9 03/31/2026
Vanguard Capital Management, LLC 3.53 5,452,762 +0.0 03/31/2026
Samsara BioCapital, LLC 2.22 3,428,571 +0.0 06/30/2026
Geode Capital Management, LLC 2.02 3,121,578 +13.7 03/31/2026
Kohlberg Kravis Roberts & Co LP 1.97 3,036,076 +0.0 03/31/2026
State Street Corp 1.51 2,325,859 +4.6 03/31/2026
Two Sigma Investments LLC 1.46 2,259,412 -1.9 06/30/2026

Funds

Funds CHRS
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 2.56 3,953,617 +0.0 07/31/2026
HBM Healthcare Investments AG Ord 2.40 3,714,285 +0.0 06/30/2026
iShares Russell 2000 ETF 2.05 3,169,372 -0.6 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?